Improved the health of premature infants and achieved the phase 3 clinical primary endpoint with innovative insulin preparation

Elgan Pharma today announced positive results from a Phase 3 clinical trial evaluating the safety and efficacy of ELGN-GI. Elgn-gi is an enteral insulin preparation for the treatment of intestinal malabsorption that leads to feeding intolerance in premature infants. The results showed improved gastrointestinal (GI) function and fewer life-threatening preterm

Read More
Share :

Five myths about AIDS

Since its discovery in 1981, AIDS has infected 76 million people worldwide and killed 35 million. It has become a major public health and social problem. In 38 years of exploration, people are also overcoming misconceptions about AIDS. A misunderstanding: AIDS causes immediate onset and death The incubation period from

Read More
Share :